In a recent interview, Michael Busch discusses the FDA and CDC’s decision to require Zika testing for all blood donors. Those donations infected with Zika are flagged, and the nationwide testing allowed Busch and his team to pull samples and follow up with donors to try to enroll them in research studies, such as REDS-III Zika, helping to further assure the safety of the nation’s blood supply.
Dr. Satish Pillai and collaborators from the Gladstone Institutes, Stanford, UCSF, and Johns Hopkins University are taking on the challenge of identifying biomarkers that could speed up the development of a cure for HIV-infected individuals. To find biomarkers, the researchers will use banked blood and plasma samples from HIV-infected volunteers who participated in various clinical trials.
[Image posted with permission from Gladstone Institutes]
Dr. Custer discusses the early effects of the FDA’s policy change observed within BSI blood centers from an indefinite donor deferral to a 1-year deferral for men who have sex with men (MSM). In this preliminary analysis, while the sample size is small, as expected the early data suggest higher rates of prevalent infection in some first time MSM donors. Longer periods of post-implementation data collection are necessary to be able to answer the most important question of whether there has been any change in the residual risk of infections in donated blood.
[Image posted with permission from AABB]
Dr. Custer received the 2017 Hemphill-Jordan Leadership Award at the AABB annual meeting for his long-term contributions to blood safety research since 2003, and his significant influence in helping U.S. policy-makers revise and set blood donation regulations. Through his consistent willingness to lend expertise and mentorship to colleagues and peers around the world, Custer was a worthy recipient for the award that honors leaders in transfusion medicine and cellular therapy.
Edward Murphy, MD, MPH, and Nareg Roubinian, MD, MPHTM, have been leading the Severe Transfusion Reactions including Pulmonary Edema (STRIPE), as part of REDS-III. STRIPE, a case-control study, examines both transfusion and clinical data to better characterize risk factors and outcomes for Transfusion-Associated Circulatory Overload (TACO). In addition, the STRIPE study includes biospecimen collection to allow study of cytokines and other biomarkers in the diagnosis and pathogenesis of TACO.
Blood Systems Research Institute (BSRI) today announced a collaboration to more precisely and efficiently measure the human immunodeficiency virus (HIV) latent reservoir in clinical samples using the Panther system from Hologic, Inc. – a fully automated molecular diagnostics platform that provides test consolidation, random-access sample loading, and proven assay chemistry.